DBV TECHNOLOGIES |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.783 EUR | -0.76% |
|
+0.38% | -57.65% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
DBV Technologies specializes in developing solutions for diagnosing and treating food allergies (primarily to peanuts and cow's milk) using a patch (Viaskin®) that administers active ingredients into the top layers of the skin.
Sector
Pharmaceuticals
Calendar
28/07/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
0.789
EUR
Average target price
6
EUR
Spread / Average Target
+660.46%
| 1st Jan change | Capi. | |
|---|---|---|
| -57.65% | 82.87M | |
| +6.45% | 72.01B | |
| +30.80% | 10.39B | |
| +41.28% | 5.26B | |
| -18.53% | 4.64B | |
| +18.24% | 3.7B | |
| +26.86% | 2.3B | |
| -39.52% | 1.8B | |
| -45.54% | 1.7B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- DBV Stock
- News DBV Technologies
- JMP Securities Adjusts Price Target on DBV Technologies to $5 From $8, Maintains Market Outperform Rating
